Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03417804
Other study ID # 2017.156(133-DEFI/125-CES)
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 18, 2018
Est. completion date November 1, 2019

Study information

Verified date June 2021
Source Centro Hospitalar do Porto
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is an epidemiological multicenter, observational, prospective study, designed to determine the incidence of postoperative residual neuromuscular blockade - defined by a TOF (train-of-four) ratio < 0.9 - at PACU arrival. Subjects aged at least 18 years old (n=360) admitted for different types of elective surgical procedures requiring general anesthesia with neuromuscular blocking agents will be included.


Description:

This is a multicenter, observational/non-interventional study involving adult patients undergoing different types of elective surgical procedures requiring general anesthesia with neuromuscular blocking agents. The study will have two periods: - Period 1 - Evaluation at PACU arrival. - Period 2 - Collection of hospital patient discharge data. A total of 360 patients will be included from approximately 10 centers in Portugal, where the PACU is adjacent to the Operating Room (OR). Each center should recruit between 30 and 40 patients. Each subject is considered to be enrolled in the study when the subject has provided written informed consent. Enrollment will be stopped when approximately 360 patients are recruited. A subject is considered to have completed the trial after all of the protocol specified activities are completed. A subject is considered to have discontinued after he/she has withdrawn consent or has been discontinued. Overall, study start is when the first site is initiated and study ends at database lock. During the routine preoperative anesthesia visit the patient will be asked to participate in the study. A description of the study will be provided to the patient by the investigator or qualified designee and any questions will be properly answered. If the patient agrees to participate in the study an informed consent form (ICF) will be signed. Consent must be documented by the subject's dated signature or by the subject's legally acceptable representative's dated signature on a consent form along with the dated signature of the person conducting the consent discussion. A copy of the signed and dated consent form should be given to the subject before participation in the study. The initial informed consent form, any subsequent revised written informed consent form and any written information provided to the subject must receive the IRB/ERC's (Institutional Review Board) ) approval/favorable opinion in advance of use. The subject or his/her legally acceptable representative should be informed in a timely manner if new information becomes available that may be relevant to the subject's willingness to continue participation in the study. All consented subjects will be given a unique patient number that will be used to identify the subject for all procedures. Each subject will be assigned only one patient number. Immediately after patient arrival in the PACU and as soon as clinically adequate (basic monitoring and oxygen therapy in place) the anesthesiologist assigned to the PACU (who was not involved in the anesthetic procedure) will collect demographic data (gender, age, weight, height), vital signs (heart rate, blood pressure, oxygen saturation and temperature). Neuromuscular blockade (TOF Ratio) will be measured. Clinical history, co-morbidities, surgical diagnosis, ASA (American Society of Anesthesiology) classification and perioperative medication data (dosage and last administration time) will be collected as well. As this is an observational study, intra-operative monitoring of neuromuscular blockade will not be mandatory by protocol and will be left at the discretion of the anesthesiologist as according to the clinical practice. Only information about whether this evaluation was performed or not, and if yes if it was used quantitative or qualitative methods, will be collected in the CRF (case report form) . Neuromuscular blockade evaluation Neuromuscular blockade will be evaluated using a quantitative method. Three consecutive TOF stimulations will be applied. In case these 3 measures differ more than 20%, another sequence of 3 consecutive TOF measurements will be considered. If after the 2nd sequence the 3 consecutive TOF measurements still differ more than 20% between the maximum and the minimum the patient will be excluded. This study will reflect real life clinical practice. The anesthetic technique in terms of drugs and type of monitoring used will be of entire responsibility of the anesthesiologist. All study activities will be consistent with EU (European Union) directive 2001/20/EC section for non- interventional studies : - NMBAs (neuromuscular blocking agents) and reversal agents (as well as all drugs which will be used during the anesthesia) administration will be done in accordance with routine anesthesiology practice and labeling of these medicine products; - No further interventional means, methods or procedures, are scheduled for subjects, which would otherwise not be applied; - Furthermore, there will be no additional visits to the hospital or a mandatory visit schedule, deviating from daily clinical practice.


Recruitment information / eligibility

Status Completed
Enrollment 366
Est. completion date November 1, 2019
Est. primary completion date July 16, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years of age or older; - Informed consent signed; - Admission for elective surgery; - Administration of non-depolarizing NMBAs during surgery Exclusion Criteria: - Admission for emergency surgery; - Reoperation on the same hospital admission; - More than 10 minutes elapsed between extubation and neuromuscular block monitoring at PACU

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Portugal Hospital Prof. Fernando Fonseca, EPE Amadora
Portugal Centro Hospitalar Baixo Vouga Aveiro
Portugal Centro Hospitalar Universitário de Coimbra Coimbra
Portugal Centro Hospitalar Lisboa Norte Lisboa
Portugal Hospital Pedro Hispano Matosinhos
Portugal Centro Hospitalar Tamega Sousa Penafiel
Portugal Centro Hospitalar do Porto Porto
Portugal Centro Hospitalar S. João Porto
Portugal Centro Hospitalar Vila Nova Gaia/Espinho Vila Nova De Gaia
Portugal Centro Hospitalar Tondela Viseu Viseu

Sponsors (1)

Lead Sponsor Collaborator
Centro Hospitalar do Porto

Country where clinical trial is conducted

Portugal, 

Outcome

Type Measure Description Time frame Safety issue
Other Association of Postoperative Residual Blockade and ASA Status To evaluate the association of postoperative residual blockade with co- morbidities and ASA status no more than 10 minutes after operating room exit
Primary Percentage of Patients With Postoperative Residual Neuromuscular Blockade Percentage of patients arriving PACU with a TOF ratio < 0.9 measured as average of 3 consecutive TOF stimulations No more than 10 minutes after operating room exit
Secondary Percentage of Patients With Severe Residual Postoperative Neuromuscular Blockade Percentage of patients with severe postoperative residual neuromuscular blockade defined by a TOF ratio < 0.7 no more than 10 minutes after operating room exit
Secondary Association of Postoperative Residual Blockade and the Use of Reversal Agents Association of postoperative residual blockade and the use of reversal agents (neostigmine, sugammadex or none) no more than 10 minutes after operating room exit
Secondary Association of Postoperative Residual Blockade and the Use of Intra-operative Monitoring of Neuromuscular Blockade To evaluate the association of postoperative residual blockade and the use of intra-operative monitoring of neuromuscular blockade no more than 10 minutes after operating room exit
See also
  Status Clinical Trial Phase
Recruiting NCT05558969 - The Effect of Magnesium Use in Reversal of Neuromuscular Block With Sugammadex N/A
Completed NCT03168308 - Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients Phase 4
Not yet recruiting NCT03978780 - Erector Spinae Block vs. Placebo Block Study N/A
Completed NCT02912039 - Electromyographic Assessment of the TetraGraph in Normal Volunteers
Completed NCT02892045 - Mindray Neuromuscular Transmission Transducer
Completed NCT03427385 - Minimum Local Anesthetic Dose for Adductor Canal Block N/A
Completed NCT01450813 - The Effect of Neuromuscular Blockade on the Composite Variability Index (CVI) During Laryngoscopy N/A
Completed NCT00535496 - Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698) Phase 3
Recruiting NCT05794503 - Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex Early Phase 1
Not yet recruiting NCT05993390 - Pharmacological Reversal of Neuromuscular Blockade in Critically Ill Patients N/A
Recruiting NCT04609410 - Bleeding in Laparoscopic Liver Surgery N/A
Terminated NCT03649672 - The Validity and Tolerability of Awake Calibration of the TOF Watch SX Monitor N/A
Completed NCT05687253 - Evaluation of Intubation Conditions Following BX1000 or Rocuronium in Subjects Undergoing Surgery Phase 2
Completed NCT05474638 - Comparison of Mechanomyographic 100 Versus 200 Hz 5 Second Tetanic Fade Ratios During Neuromuscular Block Recovery N/A
Completed NCT05120999 - Comparison of Onset of Neuromuscular Blockade With Electromyographic and Acceleromyographic Monitoring
Completed NCT03572413 - The Effect of Low Pressure Pneumoperitoneum During Laparoscopic Colorectal Surgery on Innate Immune Homeostasis. Phase 4
Completed NCT03608436 - The Effect of Low Pressure Pneumoperitoneum During Laparoscopic Colorectal Surgery on Early Quality of Recovery Phase 4
Recruiting NCT02930629 - Residual Block in Postoperative Anaesthetic Care Unit N/A
Completed NCT02932254 - Magnesium Sulfate Effect Following the Reversal of Neuromuscular Blockade Induced by Rocuronium With Sugammadex Phase 4
Completed NCT01828385 - Effect of Magnesium on the Recovery Time of Neuromuscular Blockade With Sugammadex Phase 4